SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is attracting attention as traders speculate on the company's potential M&A activity to address looming patent cliffs for key drugs like Eliquis and Opdivo. The community is actively debating the likelihood of a major deal, with discussions centering on whether the company will prioritize bolt-on acquisitions or pursue larger, transformative mergers.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium is experiencing significant volatility as the community debates its long-term viability, with some traders citing potential short squeeze opportunities and adoption in city-wide network projects, while others express concerns over supply inflation, network utility, and past management decisions.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics Holdings is trending as investors debate its long-term viability, focusing on high cash burn rates, management's historical performance, and the potential for dilution despite positive revenue growth and recent technological advancements. Sentiment remains polarized, with bulls pointing to the commercial potential of the Eversense 365 system and institutional accumulation, while bears emphasize a history of reverse splits and concerns over operational execution.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is receiving attention following reports that it proactively pulled jalapeños from some locations due to a potential link to a salmonella outbreak in Minnesota. While some traders are expressing concern over the potential for negative headlines to impact brand trust and sales, others view the pullback as a buying opportunity, noting the company's quick response and confirmation from health officials that there is no ongoing risk.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense and Space Technologies, and Starlab Space Stations. The Defense and Space Technologies segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyager Technologies is trending as investors react to strong quarterly earnings, where the company exceeded revenue and backlog estimates, alongside ongoing optimism surrounding its defense contracts and lunar infrastructure initiatives. While the community shows enthusiasm for its growth potential as a space and defense play, some traders expressed frustration over recent volatility and price underperformance compared to the broader space sector.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

ARS Pharmaceuticals is trending following a significant analyst upgrade and institutional accumulation, with market participants closely monitoring the upcoming CVS Caremark formulary decision and competitive dynamics with Aquestive Therapeutics. Discussions remain divided between those anticipating a major short squeeze and near-term catalysts, and others expressing skepticism regarding the company's high cash burn, aggressive spending, and long-term commercial execution.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

The community conversation is largely fragmented, with many traders debating whether to continue holding through a period of stagnation or rotating capital into newer, lower-market-cap meme coins. While some long-term holders remain optimistic about a potential price recovery and future burns, others express frustration with the lack of momentum and price performance.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

The community discussion remains heavily centered on long-term accumulation and staking strategies, with investors expressing frustration over recent price stagnation despite ongoing infrastructure developments and partnership announcements. Many traders are positioning for potential long-term gains, citing the need for broader enterprise adoption and legislative clarity as the primary catalysts for a future price breakout.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTX is trending as traders speculate on the potential for a rebound in leveraged exposure to MicroStrategy, with many debating the impact of upcoming reverse stock splits and the influence of volatile Bitcoin price action. While some community members view current low price levels as a buying opportunity, others warn of the risks associated with daily leveraged decay and the long-term deterioration of such ETFs.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Internet Computer (ICP) is experiencing significant community debate driven by persistent price weakness and concerns over long-term tokenomics, despite continued technical development and ecosystem activity. While some traders remain committed to its potential as decentralized infrastructure for AI and sovereign cloud applications, others express frustration with the lack of price appreciation and recent community sentiment shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences: Wells Fargo 21st...

Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?

Is it a good or bad thing when a stock experiences a golden cross technical event?

SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future 

Equity

ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.

ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’

ARCT stock was most recently buoyed by positive late-stage results from Merck and Moderna on their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.


SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology

Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.

ARCT Defies mRNA Selloff And Extends Rally As Moderna, BioNTech Shares Pull Back

The rally around MRNA names began on Wednesday after Merck and Moderna reported positive late-stage results for their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.


Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +21.50% and +18.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended June 30, 2026, and provided corporate updates. We...

Exelixis (EXEL) Tops Q2 Earnings Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of +5.81% and -0.99%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +641.18% and +22.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

• Reported GAAP EPS of -$0.84 down -147.06% YoY
• Reported revenue of $2.96M down -89.54% YoY

Arcturus Therapeutics faces significant revenue declines following the termination of its CSL collaboration, necessitating increased capital requirements and independent commercialization efforts that could strain financial resources and management focus.

Arcturus Therapeutics regained strategic control of its vaccine portfolio and established a new strategic manufacturing and clinical services collaboration with Thermo Fisher to advance its ARCT-032 cystic fibrosis therapeutic candidate.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Bearish Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARCT Arcturus Therapeutics Holdings Inc

Fundamentals

Latest ARCT News